Mealey's (June 21, 2019, 1:46 PM EDT) -- WASHINGTON, D.C. — In a June 21 ruling, the Federal Circuit U.S. Court of Appeals found no error in findings by the Patent Trial and Appeal Board that eight claims of a patented composition of largely insoluble azole antifungal drugs would be anticipated or rendered obvious by prior art (Mayne Pharma International Pty Ltd. v. Merck, Sharpe & Dohme Corp., No. 18-1593, Fed. Cir.)....